Actelion

Actelion_Logo_mesa

Actelion Pharmaceuticals Hellas S.A

Actelion is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for significant unmet medical needs.

Actelion is the leader in the science and medicine of Pulmonary Arterial Hypertension (PAH), with over 15 years of experience. Our understanding of the complex pathways and molecular mechanisms of this disease has enabled the development of tailored medicines that can make a real difference to patient outcomes with a portfolio of PAH treatments that covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral and intravenous medications.

The global innovation of Actelion is not only focused to the treatment of Pulmonary Arterial Hypertension but also to the treatment of other rare diseases, such as the Digital Ulcers in patients suffering from Scleroderma, Gaucher Disease Type 1, Niemman-Pick Disease Type C and Mycosis Fungoides – type of Cutaneous T-cell Lymphoma.

Today, Actelion is characterized as a “new” generation pharmaceutical company as it provides effective disease treatments combining the innovation, speed and flexibility along with the discipline and the excellent structure of operations globally. The dedication and expertise of Actelion in rare diseases allows the company to achieve great results in the development of innovative medicines, which can potentially cover a wide range of medical needs.

Founded in late 1997, in Basel-Switzerland, Actelion has now  over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico.

In Greece, Actelion is dynamically active for more than 12 years, implementing innovative initiatives  aiming to provide support to Greek patients with rare diseases. At the same time, Actelion Hellas significantly contributes to the creation of new innovative paths between Greece and key “Centre of excellence” abroad, by offering scholarships to specialized doctors.

Actelion headquarters are in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®)

Address:
6 – 8, Agisilaou Str., “Blue Land Centre” GR-151 23 Ag. Thomas, Marousi
Telephone:
+30 210 6752 500
Fax:
+30 210 6752 532